Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | endometrial cancer |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, RIP |
| Sample | endometrial adenocarcinoma tissues, cell lines (Ishikawa, HEC-1B) |
| Expression Pattern | down-regulated |
| Function Description | lower MEG3 expression in endometrial carcinoma tissues than in normal endometrial tissues.MEG3 overexpression inhibited endometrial cancer cell proliferation, invasion, and metastasis; promoted apoptosis; and inhibited the activation of the phosphoinositide 3-kinase (PI3K)/m-TOR signaling pathway.MEG3 can combine directly with PI3K.MEG3 could significantly suppress tumor growth. |
| Pubmed ID | 29094270 |
| Year | 2017 |
| Title | LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway. |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for endometrial cancer | OMIM COSMIC |